Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia

Alfonso Quintás-Cardama, Jorge E. Cortés, Hagop Kantarjian

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

The tyrosine kinase inhibitor (TKI) imatinib constitutes the current first-line therapeutic approach for patients with chronic myeloid leukemia. The success of imatinib relies on its potent inhibitory activity against the Bcr-Abl kinase that drives the pathogenesis of this disorder. The vast majority of patients treated with imatinib as a single agent will achieve a complete cytogenetic response. However, a subset of patients will develop imatinib resistance, frequently associated with mutations within the Abl kinase domain. In this setting, treatment with the second-generation TKIs nilotinib and dasatinib has proved highly efficacious. While therapy with these Bcr-Abl TKIs is generally well tolerated, adverse events are common and can result in treatment interruptions that compromise clinical responses. Herein, we discuss some of the toxicities characteristically associated with TKI therapy and provide practical approaches to the clinical management of these adverse effects.

Original languageEnglish (US)
Pages (from-to)S82-S88
JournalClinical Lymphoma and Myeloma
Volume8
Issue numberSUPPL. 3
DOIs
StatePublished - Mar 2008
Externally publishedYes

Keywords

  • Bcr-Abl
  • Dasatinib
  • Imatinib
  • Myelosuppression
  • Nilotinib
  • Peripheral edema
  • Pleural effusion

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this